Table 4

Pharmacokinetic parameters of irinotecan and metabolites in patients who did not receive enzyme-inducing anticonvulsantsa

Dose (mg/m2)No. of patientsCmaxAUC (μm·h)Irinotecan clearance (liter/h/m2)
Irinotecan (μm)SN-38 (nm)SN-38G (nm)IrinotecanSN-38SN-38G
11231.3 ± 0.232 ± 13150 ± 197.3 ± 1.60.18b2.3 ± 0.721.5 ± 4.8
11772.3 ± 1.946 ± 28206 ± 12310.8 ± 6.90.45 ± 0.382.4 ± 2.014.8 ± 9.8
12531.4 ± 0.251 ± 68259 ± 1735.8 ± 1.61.55 ± 0.01c2.6 ± 1.529.0 ± 6.2
Mean ± SD18.8 ± 10.6
  • a Mean ± SD at each dose level based on measurement of the total plasma concentration (lactone + carboxylate) of each compound.

  • b Parameter could not be estimated in 2 patients (n = 1).

  • c Parameter could not be estimated in 1 patient (n = 2).